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Abstract  A simple gas chromatography method with mass detection (GC-MS) for the determination of chloropyramine 
active pharmaceutical ingredient (API) in tablets was developed. Chromatographic separation was achieved on a fused silica 
ZB-5 capillary column (30 m x 0.25 mm i.d. x 0.25 µm film thickness). Acquisition was performed in selected ion monitoring 
mode (SIM) with target ion (58 m/z) and reference ions (71 m/z, 125 m/z). The method was validated in respect system 
suitability, specificity, linearity, range accuracy and precision, limit of detection (LOD), limit of quantification (LOQ), 
specificity, robustness and stability. The advantages of this method include simple sample treatment, short elution time (less 
than 15 min) and short analysis time (less than 25 min). The proposed method could be applicable for routine analysis in 
pharmaceutical analytical laboratories. 
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1. Introduction 
Chloropyramine is a first generation antihistamine drug 
approved in some Eastern European countries for the 
treatment of allergic conjunctivitis, allergic rhinitis, 
bronchial asthma, and other allergic conditions [1]. 
Chloropyramine is known as a competitive reversible 
H1-receptor antagonist. By blocking the effects of histamine, 
the drug inhibits the vasodilatation, increased vascular 
permeability, and tissue edema associated with histamine 
release in the tissue [2]. 
Chloropyramine is an antihistamine of ethylenediamine 
group indicated for the treatment of several pathologies due 
to its anti-allergic and anti-inflammatory effects [3, 4]. This 
antihistamine manufactured under different trade names as 
Synopen®, Suprastin®, Avapena ®) etc. is still available in 
various pharmaceutical forms as: ointments and creams for 
topical application containing 0.1% (W/W) chloropyramine 
hydrochloride, injections containing 20 mg/mL 
chloropyramine hydrochloride, and tablets for oral 
administration containing 25 mg chloropyramine 
hydrochloride [5, 6].  
Chloropyramine hydrochloride (CHCl) is a white powder 
with the chemical name(N-[(4-chlorophenyl)methyl]-N',N'-
dimethyl-N-pyridin-2-ylethane-1,2-diamine hydrochloride) 
with the chemical formula C16H21Cl2N3 and molecular 
weight (average mass) 326.264 Da. The chemical structure  
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of CHCl is shown in Figure 1. 
 
Figure 1.  Chemical structure of chloropyramine hydrochloride  
Gravimetric and spectrophotometric methods have been 
described for the simultaneous determination of 
chloropyramine, amitriptiline, imipramine and antazoline in 
coated tablets [7]. A novel High - performance liquid 
chromatography method (HPLC) for the simultaneous 
determination of antihistamine bamipine, sympathomimetic 
amines and dextromethorphan in bulk drug material has been 
developed [8]. HPLC method was also reported for the 
determination of antihistamines pheniramine and pyrilamine 
in two over the counter cold medications [9]. HPLC remains 
the analytical method of choice, especially for analysis of the 
topical formulations and tablets, owing to their complex 
composition [10]. 
In the last two decades a remarkable advancement in the 
hyphenated techniques and its application in pharmaceutical 
analysis have been achieved. A variety of hyphenated 
techniques such as liquid chromatography tandem mass 
spectrometry (LC-MS), gas chromatography with mass 
detection (GC-MS) etc. have been applied in the analysis of 
pharmaceuticals [11]. However, up to our knowledge, no 
GC-MS method for the analysis of chloropyramine 
hydrochloride in tablet formulations has been described. 
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The aim of this study was to develop a simple, rapid, 
specific, precise and accurate method based on GC-MS 
technique for the determination of chloropyramine 
hydrochloride in tablets. The method was validated in 
respect of system suitability, specificity, linearity range, 
accuracy, precision, limit of detection (LOD), limit of 
quantification (LOQ), selectivity, robustness and stability 
[12, 13]. 
2. Materials and Methods 
2.1. Reagents and Standards 
Commercially available samples, Suprastin® for oral use 
containing 25 mg chloropyramine in the form of 
chloropyramine hydrochloride were used in this study. In 
addition to the active ingredient, each tablet contains stearic 
acid, gelatine, sodium carboxymethyl starch (type A) talc, 
potato starch, and lactose monohydrate. Chloropyramine 
hydrochloride purity ≥ 99.8% was obtained from Fluka, 
Germany Chloropyramine base purity ≥ 99.7% was obtained 
from Alkaloid, Macedonia. Chloroform (Merck, Germany) 
gas chromatography grade was used for the extraction and 
preparation of standard solutions. Ammonium hydroxide 
(25%, V/V) was obtained from Fluka, Germany. 
Hydrochloric acid (37%, V/V) was obtained from Sigma 
Aldrich, Germany. Anhydrous sodium sulfate was obtained 
from Merck, Germany. Water was obtained by double 
distillation. 
2.2. Preparation of Solutions  
Chloropyramine standard stock solution with the 
concentration of 1mg/mL (i) was prepared in chloroform by 
transferring 10 mg of chloropyramine standard accurately 
weighted to a 10 mL volumetric flask and filled up with 
chloroform to the mark. An aliquot of 1 mL of the standard 
stock solution (i) was transferred to a 25 mL volumetric flask 
and was diluted with chloroform to obtain the concentration 
of 40 μg/mL (standard stock solution ii). 
Working standard solutions, in a concentration range of 
0.4 – 4.0 μg/mL, were prepared by dilution of the standard 
stock solution (ii) with chloroform. 1 μL of each 
concentration was injected into the GC-MS system.  
Twenty tablets were weighed and net content of each 
tablet was calculated. An aliquot of tablet powder equivalent 
to 10 mg CHCl was accurately weighed and and dissolved in 
approximately 10 mL 0.5 M HCl. The solution was 
quantitatively transferred into the 100 mL separatory funnel. 
pH value of the solution was adjusted to 9-10 with 25% 
NH4OH (V/V). After alkalization chloropyramine base was 
extracted with 40 mL chloroform. Chloroform layer was 
transferred through anhydrous sodium sulfate into the 50 mL 
volumetric flask and was filled up with chloroform to the 
mark. 0.1 mL of this solution was transferred into the 10 mL 
volumetric flask and filled up with chloroform to the mark. 
The solution was filtered through a 0.22 μm Millipore 
membrane filter. 2 mL of the filtrate were transferred into the 
auto - sampler vial. 1 μL were injected into the injection port 
of GC-MS. 
2.3. Instrumentation and Chromatographic Conditions 
The method was performed on a Shimadzu GC-MS model 
QP 2010 Ultra. Chromatographic separation was achieved 
on a fused silica ZB-5 capillary column (30 m x 0.25 mm i.d. 
x 0.25 µm film thickness), supplied by Phenomenex 
(Torrance, USA). Helium purity 99.99999% was used as 
carrier gas.  
Operating conditions were as follows: injection port 
temperature, 250°C; injection volume 1 μL in the splitless 
mode with a sampling time of 1 min (injection pressure   
250 kPa); oven temperature programme: initial column 
temperature was 180°C, increased with the rate of 5°C/min 
to 240°C and held for 5 min. The total run time of the 
chromatographic analysis was 14 min. The column 
equilibration time was 3 min, purge flow was 6 mL/min, and 
carrier gas constant flow was 0.62 mL/min. Ion source 
temperature was set at 200°C, the interface temperature was 
250°C, the auxiliary temperature was 250°C, and the 
quadrupole temperature was 150°C. 
2.4. Method Validation  
The proposed method was validated according to the 
guidelines set by the International Conference on 
Harmonization for validation of analytical procedures [12, 
13]. The parameters used to validate the method of analysis 
were: system suitability, specificity, linearity and range, 
precision, limit of detection (LOD) and limit of 
quantification (LOQ), accuracy, robustness, and stability. 
2.4.1. System Suitability 
System suitability testing is an integral part of gas 
chromatographic method validation performed to check and 
ensure on-going performance of a chromatographic system. 
The system repeatability was estimated by 6 repeated 
injections of working standard solutions at 100% of test 
concentration (10 μg/mL chloropyramine). The system 
parameters were calculated according to the 
recommendation of the United States Pharmacopoeia [14, 
15]. The limits for system suitability parameters suggested 
in the FDA guideline on ״Validation of Chromatographic 
Methods״ [16] were used as acceptance criteria.  
2.4.2. Specificity 
Specificity is the ability to asses unequivocally the analyte 
in the presence of components which maybe expected to be 
present (impurities, products of degradation, matrices, etc.) 
[14, 15]. Specificity of the proposed was demonstrated by 
spiking the grounded tablet formulation with a known 
quantity of CHCl standard, then checking for the 
interference with the placebo. 
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2.4.3. Linearity and Range  
For evaluation of linearity the calibration curve was 
obtained at 10 concentrations levels of chloropyramine 
standard solutions (0.4 – 4.0 μg/mL). Additionally, to 
improve the specificity, we evaluated linearity of 
chloropyramine in the presence of excipients. For that 
purpose, we spiked placebo samples with one stock active 
solution at six concentration levels (0.8– 8.0 μg/mL). The 
solutions (1 μL) were injected in triplicate into a 
chromatographic system with the previously given 
chromatographic conditions. For evaluation of linearity, the 
peak area and concentrations were subjected to a least square 
regression analysis in order to calculate calibration equation 
and determination coefficient. 
2.4.4. Precision 
The precision of the analytical procedure (intra-assay 
precision) was investigated by analyzing six sample 
solutions obtained by multiple sampling of the same 
homogenous sample under the prescribed conditions (at  
100% of the test concentration of chloropyramine (10 μg/mL) 
on the same day, by the same analyst and using the same 
equipment. The intermediate precision of the analytical 
procedure was investigated by analyzing sample solutions on 
three consecutive days. The precision of the analytical 
procedure was expressed as the relative standard deviation of 
a series of measurements.  
2.4.5. Limit of Detection and Limit of Quantification 
Limit of detection (LOD) and limit of quantification (LOQ) 
of the proposed method were determined by consecutively 
injecting low concentrations of the standard solutions (0.02 – 
0.2 μg/mL) using the proposed GC–MS method. LOD and 
LOQ were calculated in accordance with ICH guidelines [14, 
15] as follows: LOD = 3.3 SD/S and LOQ = 10 SD/S, where 
SD is the standard deviation of the response (y intercept) and 
S is the slope of the calibration curve obtained. 
2.4.6. Accuracy 
To study the accuracy of the proposed analytical method, 
recovery tests were conducted using the standard addition 
method. To discover whether excipients interfered with the 
analyte, known amounts of standard were added to grinded 
tablet formulation samples and the resulting mixtures were 
analyzed by the proposed methods. The percent of recovery 
was calculated as follows: 
 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 (%) = (𝐶𝐶𝐶𝐶 − 𝐶𝐶𝐶𝐶)|𝐶𝐶𝐶𝐶) 𝑥𝑥 100,      (1) 
Where Cυ is the total amount of CHCl measured after 
standard addition, Cu the amount of CHCl in the drug 
formulation, and Ca the amount of CHCl added to the 
formulation. 
2.4.7. Method Robustness 
The capacity of the proposed method to remain unaffected 
by small (deliberate) variations in parameters was evaluated 
in order to determine method robustness. Changes were 
made to the following method parameters: concentration of 
HCl (± 10%), pH value of the solution after addition of 25% 
NH4OH (± 5%), and temperature (± 3%).  
2.4.8. Stability of the Sample Extracts 
For this study five quality control (QC) samples with the 
nominal concentration of 1 mg/g CHCl were used. After the 
sample preparation according to the procedure described 
above (2.2), obtained extracts were stored at -20°C over the 
period of 12 weeks. The concentration of chloropyramine 
was determined according to the procedure described in 2.3. 
3. Results and Discussion 
3.1. Method Optimization 
Because of poor solubility of chloropyramine 
hydrochloride (salt) in water and in the majority of organic 
solvents (polar and non-polar), in our experiment as a 
suitable solvent for chloropyramine hydrochloride 
dissolution we used 0.5 M HCl. Iliaszenko et al. used 0.5 M 
HCl for dissolution of several tertiary amine hydrochloride 
drugs in coated tablets, prior their spectrophotometric 
determination [7].  
Chloropyramine base was deliberated from the salt by 
addition of 25% NH4OH (V/V) to pH 9-10. Extraction of the 
free base was efficiently performed with chloroform. 
In order to improve specificity and selectivity and 
minimize interferences from ointment or solvent systems 
that may occur in spetrophotometric or HPLC 
determinations, we performed the analysis using GC-MS 
system. In our previous study, we use the same GC-MS 
technique, after the isolation of chloropyramine from 
ointments [17]. Selectivity was obtained by operating in 
selected ion monitoring (SIM) mode with target ion (58 m/z) 
and reference ions (71 m/z, 125 m/z). Figure 2 depicts the 
mass spectrum of chloropyramine. 
 
Figure 2.  Mass spectrum of chloropyramine 
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3.2. Method Optimization 
3.2.1. System Suitability 
The results of system suitability test were found within the 
acceptable range [16] indicating that the system was suitable 
for the intended analysis (Table 1). 
Table 1.  Results of system suitability test 
Parameter Results Parameter limit 
RSD of retention time 0.12% <1% 
RSD of peak area 0.25% <1% 
Capacity factor k, 5.52 >2% 
Theoretical plate 12,345 >2000 
3.2.2. Specificity 
In the specificity study, standard solutions of 
chloropyramine and the sample solution were injected and a 
single peak was obtained for chloropyramine, which 
indicates that that there was no interference from the 
excipient used or from the chemicals.  
3.2.3. Linearity and Range 
In the present study, linearity was studied in the 
concentration range 0.4 – 4.0 μg/mL chloropyrmine and the 
following regression equation was found by plotting the peak 
area (y) expressed in AU versus the chloropyramine 
concentration (x) expressed in μg/L: y = 11178 x + 32 (r2 = 
0.9999). The determination coefficient (r2) demonstrates the 
excellent relationship between the peak area and 
concentration of chloropyramine. The calibration curve of 
chloropyramine API and chloropyramine with placebo were 
linear. The regression lines were not significantly different 
from a curve passing through the origin y = a x. (P-value of 
the slope > 0.05). The excipients had no influence and there 
was no matrix effect observed (Table 2). 
Table 2.  Characteristic of the linear regression analysis 
Parameter Chloropyramine
a 
API 
Chloropyramine  
+ excipients 
Linearity range (μg/L) 0.4 – 4.0 0.8 – 8.0 
Slope 11178 11454 
Intercept 32 65 
Determination 
coefficient (r2) 0.9999 0.9999 
SEb of the intercept 29.432 24.332 
SE of the slope 65.433 71.343 
P – value of the slope 0.395 0.386 
aMean value of 3 determinations 
bSE – Standard error 
3.2.4. Precision and Accuracy 
The variation in results obtained within a day (RSD = 
0.75%, for Suprastin® 25 mg tablets) and day to day 
variations (RSD = 0.10%) for chloropyramine determination 
was very low (≤ 2%), which confirmed the precision of the 
method. The statistical data are shown in Table 3. 
Table 3.  Precision of the method 
Precision Parameter % of declared content (X) 
RSD 
(%) 
Bias 
(%) 
Intra – assay 
precisiona 
25 mg 
tablets 99.75 0.75 0.25 
 Day 1 96.15 0.95 3.85 
Intermediate 
precisiona Day 2 96.45 0.88 3.55 
 Day 3 96.58 0.93 3.42 
 X 96.39 0.10 3.60 
an = 6 
The average recovery for the tested amounts was 99.89% 
± 0.15% (n=6). Mean recovery (Table 4) for chloropyramine 
was between 99.0 and 103.44% indicating that the developed 
method was accurate for the determination of 
chloropyramine in pharmaceutical formulation. 
Table 4.  Accuracy of the method 
Amount 
added (μg/L) 
Amount 
found (μg/L) 
Recovery 
(%) 
RSD 
(%) 
Bias 
(%) 
0.402 
0.553 
0.617 
0.398 
0.572 
0.612 
99.00 
103.44 
99.19 
0.75 
1.05 
0.98 
0.99 
3.43 
0.81 
0.720 
0.795 
0.855 
0.715 
0.790 
0.847 
99.30 
99.37 
99.06 
0.95 
0.66 
0.78 
0.69 
0.63 
0.93 
 X 99.89 0.15 0.105 
3.2.5. Limit of Detection and Limit of Quantification 
The limit of detection (LOD) and limit of quantification 
(LOQ) were 0.0132 μg/mL (corresponding to 0.0132 ng/mL 
loaded onto column) and 0.04 μg/mL (corresponding to 0.04 
ng/mL loaded onto column), respectively. 
3.2.6. Robustness 
Based on the obtained results from the method robustness 
(RSD < 2%), the proposed GC-MS analytical method were 
demonstrated to be robust (Table 5). 
Table 5.  Robustness of the method 
Change in parameter RSD (%) (n = 3) 
Molarity of HCl solution (0.55 M) 1.2 
Molarity of HCl solution (0.45 M) 1.35 
pH value (8.5) 1.67 
pH value (10.5) 1.08 
Temperature (22 °C) 0.92 
Temperature (28 °C) 0.65 
3.2.7. Stability 
The results of our investigations showed that the extracts 
were stable at -20°C within a period of 4 weeks. 
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Approximate degradation observed for 4, 8 and 12 weeks 
was 1.25%, 67.8% and 77.4%, respectively. Figure 3 shows 
chromatograms of extracts of chloropyramine base in 
chloroform over the period from 4 to 12 weeks. 
 
Figure 3.  Overlay of chromatograms of extracts of chloropyramine base 
in chloroform (1-after 4 weeks, 2- after 8 weeks and 3-after 12 weeks of 
storage at -20°C) 
4. Conclusions 
The proposed GC-MS method allows a simple, accurate, 
precise and rapid determination of chloropyramine API in 
tablets. The important features and advantages of this 
method include: simple sample extraction of small amounts 
of powdered sample at ambient temperature, relatively short 
elution time (less then 13 min) and shorter analysis time than 
in previously reported methods (less than 25min); good 
precision (RSD less than 2%) and high recovery (higher than 
99%). Furthermore, operating in SIM mode provides 
additional selectivity of the method in terms of interferences. 
The proposed method could be applicable for routine 
analysis in pharmaceutical analytical laboratories. 
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